Compare D R Horton Inc (DHI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Summit Therapeutics Inc — how do they compare? D R Horton Inc trades at $134.88 (market cap $37.99B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: D R Horton Inc is far larger — about 2.8× Summit Therapeutics Inc's market cap, and D R Horton Inc pays a 1.33% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Summit Therapeutics Inc for 16 Days on average.
| DHI | SMMT | |
|---|---|---|
Market Cap | $37.99B | $13.71B |
Volume | 2,974,460 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $26.38 |
52-Week Low | $132.53 | $12.43 |
Typical Hold Time | 46 Days | 16 Days |
Enterprise Value | $43.09B | $13.04B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $135.82, up 1.91% today, but faces a bearish technical outlook with resistance at $137. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue declined to $34.25B in 2025, and net income margin compressed to 9.15%. Analysts maintain a buy consensus with a $156.57 target, but rising mortgage rates and housing market weakness pose headwinds.
The stock offers value with a P/E of 12.95 and strong cash flow, but investor sentiment is cautious due to macroeconomic risks. Near-term performance hinges on Q3 earnings and interest rate trends. The current price near the low end of the target range suggests limited downside if fundamentals hold.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
